Suivre
Shinichiro Luke Nakajima
Titre
Citée par
Citée par
Année
Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology
OD Howes, R McCutcheon, O Agid, A De Bartolomeis, NJM Van Beveren, ...
American Journal of Psychiatry 174 (3), 216-229, 2017
8852017
Gut microbiota and major depressive disorder: a systematic review and meta-analysis
K Sanada, S Nakajima, S Kurokawa, A Barceló-Soler, D Ikuse, A Hirata, ...
Journal of affective disorders 266, 1-13, 2020
2732020
Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies
S Moriguchi, A Takamiya, Y Noda, N Horita, M Wada, S Tsugawa, ...
Molecular psychiatry 24 (7), 952-964, 2019
2422019
Kynurenine pathway in depression: A systematic review and meta-analysis
K Ogyu, K Kubo, Y Noda, Y Iwata, S Tsugawa, Y Omura, M Wada, ...
Neuroscience & Biobehavioral Reviews 90, 16-25, 2018
2362018
Kynurenic acid in schizophrenia: a systematic review and meta-analysis
E Plitman, Y Iwata, F Caravaggio, S Nakajima, JK Chung, P Gerretsen, ...
Schizophrenia bulletin 43 (4), 764-777, 2017
2072017
The potential role of dopamine D3 receptor neurotransmission in cognition
S Nakajima, P Gerretsen, H Takeuchi, F Caravaggio, T Chow, B Le Foll, ...
European Neuropsychopharmacology 23 (8), 799-813, 2013
2002013
Glutamate-mediated excitotoxicity in schizophrenia: a review
E Plitman, S Nakajima, C de la Fuente-Sandoval, P Gerretsen, ...
European Neuropsychopharmacology 24 (10), 1591-1605, 2014
1772014
Glutamatergic neurometabolite levels in patients with ultra-treatment-resistant schizophrenia: a cross-sectional 3T proton magnetic resonance spectroscopy study
Y Iwata, S Nakajima, E Plitman, F Caravaggio, J Kim, P Shah, W Mar, ...
Biological psychiatry 85 (7), 596-605, 2019
1082019
Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials
Y Iwata, S Nakajima, T Suzuki, RSE Keefe, E Plitman, JK Chung, ...
Molecular psychiatry 20 (10), 1151-1160, 2015
1052015
Neuroimaging findings in treatment-resistant schizophrenia: a systematic review: lack of neuroimaging correlates of treatment-resistant schizophrenia
S Nakajima, H Takeuchi, E Plitman, G Fervaha, P Gerretsen, ...
Schizophrenia research 164 (1-3), 164-175, 2015
1032015
Accelerating response to antidepressant treatment in depression: a review and clinical suggestions
S Nakajima, T Suzuki, K Watanabe, H Kashima, H Uchida
Progress in Neuro-Psychopharmacology and Biological Psychiatry 34 (2), 259-264, 2010
1022010
Psychosis in frontotemporal dementia
S Shinagawa, S Nakajima, E Plitman, A Graff-Guerrero, M Mimura, ...
Journal of Alzheimer's disease 42 (2), 485-499, 2014
932014
Insight and medication adherence in schizophrenia: An analysis of the CATIE trial
J Kim, M Ozzoude, S Nakajima, P Shah, F Caravaggio, Y Iwata, ...
Neuropharmacology 168, 107634, 2020
892020
Evaluation of antipsychotic dose reduction in late-life schizophrenia: a prospective dopamine D2/3 receptor occupancy study
A Graff-Guerrero, TK Rajji, BH Mulsant, S Nakajima, F Caravaggio, ...
JAMA psychiatry 72 (9), 927-934, 2015
842015
Effectiveness of the prefrontal repetitive transcranial magnetic stimulation on cognitive profiles in depression, schizophrenia, and Alzheimer's disease: a systematic review
T Iimori, S Nakajima, T Miyazaki, R Tarumi, K Ogyu, M Wada, S Tsugawa, ...
Progress in Neuro-Psychopharmacology and Biological Psychiatry 88, 31-40, 2019
812019
The evolution of antipsychotic switch and polypharmacy in natural practice—a longitudinal perspective
C Tsutsumi, H Uchida, T Suzuki, K Watanabe, H Takeuchi, S Nakajima, ...
Schizophrenia research 130 (1-3), 40-46, 2011
792011
Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D2/3 Receptors in the Ventral Striatum of Healthy Nonobese Humans
F Caravaggio, C Borlido, M Hahn, Z Feng, G Fervaha, P Gerretsen, ...
International Journal of Neuropsychopharmacology 18 (7), pyv014, 2015
762015
Dental conditions in inpatients with schizophrenia: A large-scale multi-site survey
H Tani, H Uchida, T Suzuki, Y Shibuya, H Shimanuki, K Watanabe, R Den, ...
BMC Oral Health 12, 1-6, 2012
762012
Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies
T Nakahara, S Tsugawa, Y Noda, F Ueno, S Honda, M Kinjo, H Segawa, ...
Molecular psychiatry 27 (1), 744-757, 2022
752022
The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review
P Shah, Y Iwata, E Plitman, EE Brown, F Caravaggio, J Kim, S Nakajima, ...
Psychiatry research 268, 114-122, 2018
742018
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20